Influence of innate cytokine production capacity on clinical manifestation and severity of pediatric meningococcal disease

Critical Care Medicine

Volumn 37, Issue 10, 2009, Pages 2812-2818

  Sprong, Tom ^a   Van Der Ven Jongekrijg, Johanna ^a   Neeleman, Chris ^a   Van Der Meer, Jos W M ^a   Van Deuren, Marcel ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytokines; Lipopolysaccharide; Meningitis; Neisseria meningitidis; Sepsis; Shock

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; ARTICLE; BACTEREMIA; BLOOD CULTURE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MENINGOCOCCOSIS; MORTALITY; NEISSERIA MENINGITIDIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SHOCK; SURVIVOR;

EID: 70349695923     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181ab851c     Document Type: Article

References (44)

1. Bøvre K, Frøholm LO, Gaustad P, et al.: Some agent characteristics and their coexistence related to occurrence and severity of systemic meningococcal disease in Norway, Winter 1981-1982. NIPH Ann 1983; 6:75-84
2. Van Deuren M, Brandtzaeg P, Van der Meer JWM: Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000; 13: 144-166
3. Waage A, Brandtzaeg P, Halstensen A, et al.: The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989; 169:333-338
4. Waage A, Halstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i:355-357
5. van Deuren M, van der Ven-Jongekrijg J, Vannier E, et al.: The pattern of interleukin- 1beta (IL-1beta) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections. Blood 1997; 90:1101-1108
6. Brandtzaeg P, Osnes L, Ovstebo R, et al.: Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: Identification of interleukin- 10 as a major functional deactivator of human monocytes. J Exp Med 1996; 184: 51-60
7. Lehmann AK, Halstensen A, Sørnes S, et al.: High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun 1995; 63:2109-2112
8. Derkx B, Marchant A, Goldman M, et al.: High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 1995; 171:229-232
9. Hazelzet JA, Kornelisse RF, van der Pouw Kraan TCTH, et al.: Interleukin 12 levels during the initial phase of septic shock with purpura in children: Relation to severity of disease. Cytokine 1997; 9:711-716
10. Carrol ED, Thomson AP, Jones AP, et al.: A predominantly anti-inflammatory cytokine profile is associated with disease severity in meningococcal sepsis. Intensive Care Med 2005; 31:1415-1419
11. Van Dissel JT, van Langevelde P, Westendorp RG, et al.: Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998; 351:950-953
12. Emonts M, Hazelzet JA, de Groot R, et al.: Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis 2003; 3:565-577
13. Westendorp RG, Langermans JA, Huizinga TW, et al.: Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349:170-173
14. Goldstein B, Giroir B, Randolph A: International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2-8
15. Pollack MM, Ruttimann UE, Getson PR: Pediatric risk of mortality (PRISM) score. Crit Care Med 1988; 16:1110-1116
16. van Brakel MJ, van Vught AJ, Gemke RJ: Pediatric risk of mortality (PRISM) score in meningococcal disease. Eur J Pediatr 2000; 159:232-236
17. van Crevel R, van der Ven-Jongekrijg J, Netea MG, et al.: Disease-specific ex vivo stimulation of whole blood for cytokine production: Applications in the study of tuberculosis. J Immunol Methods 1999; 222:145-153
18. de Jager W, te Velthuis H, Prakken BJ, et al.: Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 2003; 10:133-139
19. Sprong T, Stikkelbroeck N, van der Ley P, et al.: Contributions of Neisseria meningitidis LPS and non-LPS to proinflammatory cytokine response. J Leukoc Biol 2001; 70: 283-288
20. Brandtzaeg P, Ovstebo R, Kierulf P: Bacteremia and compartmentalization of LPS in meningococcal disease. Prog Clin Biol Res 1995; 392:219-233
21. Hackett SJ, Guiver M, Marsh J, et al.: Meningococcal bacterial DNA load at presentation correlates with disease severity. Arch Dis Child 2002; 86:44-46
22. Ovstebo R, Brandtzaeg P, Brusletto B, et al.: Use of robotized DNA isolation and real-time PCR to quantify and identify close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease. J Clin Microbiol 2004; 42:2980-2987
23. Sprong T, Moller ASWM, Bjerre A, et al.: Complement activation and complementdependent inflammation by Neisseria meningitidis occurs independent of lipopolysaccharide. Infect Immun 2004; 72:3344-3349
24. Netea MG, Sutmuller R, Hermann C, et al.: Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol 2004; 172:3712-3718
25. Giroir BP, Johnson JH, Brown T, et al.: The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest 1992; 90:693-698
26. Huston JM, Ochani M, Rosas-Ballina M, et al.: Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med 2006; 203:1623-1628
27. Figueroa JE, Densen P: Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4:359-395
28. Sprong T, Brandtzaeg P, Fung M, et al.: Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood 2003; 102:3702-3710
29. Welch SB, Nadel S: Treating meningococcal infections in children. Hosp Med 2002; 63: 268-273
30. Nadel S, Britto J, Booy R, et al.: Avoidable deficiencies in the delivery of health care to children with meningococcal disease. J Accid Emerg Med 1998; 15:298-303
31. Ninis N, Phillips C, Bailey L, et al.: The role of healthcare delivery in the outcome of meningococcal disease in children: case-control study of fatal and non-fatal cases. BMJ 2005; 330:1475
32. Read RC, Cannings C, Naylor SC, et al.: Variation within genes encoding interleukin- 1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease. Ann Intern Med 2003; 138: 534-541
33. Read RC, Camp NJ, di Giovine FS, et al.: An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. J Infect Dis 2000; 182:1557-1560
34. Endler G, Marculescu R, Starkl P, et al.: Polymorphisms in the interleukin-1 gene cluster in children and young adults with systemic meningococcemia. Clin Chem 2006; 52: 511-514
35. Balding J, Healy CM, Livingstone WJ, et al.: Genomic polymorphic profiles in an Irish population with meningococcaemia: Is it possible to predict severity and outcome of disease? Genes Immun 2003; 4:533-540
36. Hazelzet JA, van der Voort E, Lindemans J, et al.: Relation between cytokines and routine laboratory data in children with septic shock and purpura. Intensive Care Med 1994; 20: 371-374
37. Okusawa S, Gelfand JA, Ikejima T, et al.: Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81:1162-1172
38. Cannon JG, Friedberg JS, Gelfand JA, et al.: Circulating interleukin-1 beta and tumor necrosis factor-alpha concentrations after burn injury in humans. Crit Care Med 1992; 20: 1414-1419
39. Cannon JG, Tompkins RG, Gelfand JA, et al.: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161:79-84
40. Taniguchi T, Koido Y, Aiboshi J, et al.: Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med 1999; 27: 1262-1264
41. Fisher CJ Jr, Agosti JM, Opal SM, et al.: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334:1697-1702
42. Fisher CJ Jr, Dhainaut JF, Opal SM, et al.: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271:1836-1843
43. Opal SM, Fisher CJ Jr, Dhainaut JF, et al.: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin- 1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25: 1115-1124
44. Abraham E, Wunderink R, Silverman H, et al.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273:934-941 2818